Website:www.dcchemicals.

com
Email: info@dcchemicals.com Phone:+86-21-58447131
Marketing Center: Room 610,Building 15, Jinxiang Rd 201, Shanghai,
China

Datasheet of E-7449

Description:
E7449 is an orally bioavailable, potent, small molecule inhibitor of PARP1 and PARP2; enhances the efficacy of radiotherapy
and chemotherapy and has potent single agent anticancer activity in BRCA-deficient tumors. E7449 is an orally bioavailable,
potent, small molecule inhibitor of Poly(ADP-ribose) Polymerase (PARP)1 and PARP2. E7449 potently inhibits PARP1 and
PARP2 in a cell-free assay and potentiates the cytotoxicity of both radiotherapy and chemotherapy. The cytotoxic effect of
radiotherapy was enhanced by E7449 in clonogenic survival assays. The anti-tumor activity of the alkylating agent temozolomide
was potentiated by E7449 in a dose responsive manner in vivo in the B16-F10 melanoma isograft mouse model. Daily dosing of
E7449 as a single agent significantly inhibited tumor growth in a genetically engineered BRCA1 null mouse ovarian xenograft
model. In the BRCA1 mutant human breast cancer cell line MDA-MB-436, E7449 significantly inhibited proliferation in a long
term growth inhibition assay in vitro. Oral administration of E7449 once daily potently inhibited tumor growth in the
MDA-MB-436 xenograft model with no toxicity observed. A dose responsive pharmacodynamic effect on PARP activity was
demonstrated in MDA-MB-436 tumor tissue following administration of a single E7449 dose. The decrease in PARP activity was
sustained over several hours. The ability of E7449 to inhibit PARP activity in tumor tissue was further investigated in the H460
xenograft model. Following single oral administration of various E7449 dosages, inhibition of PARP activity in tumor tissue was
determined over time. Studies revealed that PARP is inhibited by E7449 in a time and dose dependent manner with lower doses
resulting in transient inhibition and higher doses causing more complete and sustained PARP inhibition. Conclusion: E7449 is a
potent and selective PARP1 and PARP2 inhibitor with potent anti-tumor activity in BRCA-deficient in vivo models. It also
potentiates the activity of radiotherapy and chemotherapy pre-clinically. Evaluation of E7449 in a Phase 1 study will be initiated
soon.

Chemical Information
Catalog

DC9983

Purity of current batch:

>98%

Molecular Weight (MW)

317.34

Molecular Formula

C18H15N5O

CAS No.

1140964-99-3

Solubility (25C)

DMSO

Storage

Store at -20C (desiccating conditions).

Handling:
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months.
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in
advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable
for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room
temperature for at least 1 hour.